Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 employees in 79 countries, and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Novo Nordisk Hong Kong Limited
Tel: +852 2387 8555
Distributor:
DKSH Hong Kong Limited
Tel: +852 2895 9668
Your information about complaints and side effects helps us ensure the safe use of our products. If you have experienced a complaint or a side effect to a Novo Nordisk product, we encourage you to also report this to Novo Nordisk.
Please e-mail: safety-country@novonordisk.com
or call us on
+852 2387 8555
If you or the person you are reporting on behalf of are currently suffering from severe side effects, you should contact your local doctor or other medical health professional before reporting the side effect.
All personal information reported in relation to a complaint or a side effect will be processed in accordance with applicable data protection legislation:
• Your report is used solely for the scientific evaluation of the medicine and product quality
• Side effects are filed in our global safety database and the data is regularly analysed for overall patterns
• Novo Nordisk may share reported complaints and side effects with health authorities as mandated by law. However, no personally identifiable details will be shared
• Novo Nordisk will retain the data as long as required by law
For jobs in the United States, please visit our US career site.
